Rynd Biotech
Boston, United States· Est.
Fast, painless urine test for bladder cancer recurrence using a patented 4‑biomarker panel.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Fast, painless urine test for bladder cancer recurrence using a patented 4‑biomarker panel.
Oncology
Technology Platform
Multiplex lateral flow immunoassay combined with square‑wave voltammetric electrochemical quantification of four patented urine biomarkers.
Opportunities
Rapid point‑of‑care and home diagnostics for bladder cancer recurrence; expansion to hematuria triage, prostate, and kidney cancer screening.
Risk Factors
Regulatory approval and reimbursement hurdles; need for large‑scale clinical validation; competition from established urine‑based assays.
Competitive Landscape
Competes with NMP22, UroVysion, ImmunoCyt, and emerging liquid‑biopsy platforms; differentiation lies in a patented four‑biomarker panel, electrochemical quantification, and a digital companion app.